Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055939 · ClinicalTrials.gov registry record · Phase 2
Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00055939: Completed Phase 2 study, sponsored by Daiichi Sankyo.
NCT00055939 is a Phase 2 study that has completed, run by Daiichi Sankyo. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055939, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating children who have relapsed or refractory rhabdomyosarcoma.
Interventions
- DRUG exatecan mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00055939 record still lists
NCT00055939 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00055939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00055939 about?
NCT00055939 is a clinical study titled "Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating children who have relapsed or refractory rhabdomyosarcoma.
What is the current status of trial NCT00055939?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00055939?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00055939?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia